688366.SS

Shanghai Haohai Biological Technology Co., Ltd. [688366.SS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

688366.SS Stock Summary

Earnings have grown 25.48% per last year.

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 quarters (Quarter statements)

Profit margins (0.13%) are lower than the previous year (0.16%)

688366.SS has less than 1 year of cash runway

Top 10 Correlated ETFs

688366.SS

Top 10 Correlated Stocks

688366.SS

In the News

688366.SS Financial details

Company Rating

Buy

Market Cap

14.36B

Income

416.12M

Revenue

2.65B

Book val./share

33.53

Cash/share

16.38

Dividend

0.4

Dividend %

0.4%

Employees

2.16K

Optionable

Shortable

Yes

Earnings

09 Mar 2024

P/E

Forward P/E

PEG

P/S

8.22

P/B

P/C

5.57

P/FCF

-236.98

Quick Ratio

4.3

Current Ratio

5.9

Debt / Equity

0.07

LT Debt / Equity

0.03

EPS (TTM)

2.44

EPS next Y

EPS next Q

EPS this Y

134.62%

EPS next Y

EPS next 5Y

EPS last 5Y

3.24%

Revenue last 5Y

10.59%

Revenue Q/Q

-1.39%

EPS Q/Q

-25.35%

SMA20

-16.07%

SMA50

2.17%

SMA100

-6.93%

Inst Own

Inst Trans

ROA

ROE

ROC

0.04%

Gross Margin

70%

Oper. Margin

16%

Profit Margin

13%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

77.61-120.0

52W High

-23.93%

52W Low

+18.55%

RSI

Rel Volume

1.06

Avg Volume

511.74K

Volume

540.41K

Perf Week

-4.65%

Perf Month

-16.27%

Perf Quarter

-8.93%

Perf Half Y

-14.68%

Beta

0.805

Volatility

1.25%, 7.11%

Prev Close

-3.37%

Price

91.28

Change

-1.87%

688366.SS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	8.97	7.48	9.94	12.12	15.48
Net income per share	2.08	1.3	2	1.04	2.44
Operating cash flow per share	1.96	1.48	1.94	1.33	3.92
Free cash flow per share	-0.28	0.37	0.4	-0.49	2.36
Cash per share	18.16	17.56	16.51	14.69	16.19
Book value per share	30.67	31.03	32.44	31.78	33.13
Tangible book value per share	27.49	26.95	27.65	27.13	32.94
Share holders equity per share	30.67	31.03	32.44	31.78	33.13
Interest debt per share	0.31	0.64	0.63	0.73	2.25
Market cap	16B	15.95B	22.17B	16.93B	18.47B
Enterprise value	12.83B	12.97B	19.38B	14.5B	16.14B
P/E ratio	43.15	69.35	62.95	93.79	44.38
Price to sales ratio	10.03	12.05	12.67	8.05	7
POCF ratio	45.85	60.88	64.78	73.18	27.6
PFCF ratio	-317.51	240.96	315.9	-197.15	45.95
P/B Ratio	2.93	2.91	3.88	3.07	3.27
PTB ratio	2.93	2.91	3.88	3.07	3.27
EV to sales	8.04	9.79	11.07	6.89	6.11
Enterprise value over EBITDA	23.18	32.97	35.41	31.33	27.02
EV to operating cash flow	36.76	49.49	56.61	62.7	24.11
EV to free cash flow	-254.54	195.88	276.07	-168.92	40.15
Earnings yield	0.02	0.01	0.02	0.01	0.02
Free cash flow yield	0	0	0	-0.01	0.02
Debt to equity	0.01	0.02	0.02	0.02	0.07
Debt to assets	0.01	0.02	0.02	0.02	0.05
Net debt to EBITDA	-5.73	-7.59	-5.11	-5.24	-3.91
Current ratio	10.96	8.78	7.62	6.91	5.24
Interest coverage	96.51	53.12	77.46	34.02	40.33
Income quality	0.8	1.02	0.89	0.98	1.61
Dividend Yield	0.01	0.01	0	0.01	0
Payout ratio	0.22	0.54	0.25	0.68	0.16
Sales general and administrative to revenue	0.17	0.16	0.16	0.19	0
Research and developement to revenue	0.07	0.1	0.1	0.09	0.08
Intangibles to total assets	0.12	0.15	0.17	0.17	0.06
Capex to operating cash flow	-1.14	-0.75	-0.79	-1.37	-0.4
Capex to revenue	-0.25	-0.15	-0.16	-0.15	-0.1
Capex to depreciation	-3.46	-1.47	-1.67	-1.55	-1.35
Stock based compensation to revenue	0.01	0.01	0	0.01	-0.12
Graham number	37.93	30.12	38.21	27.27	42.65
ROIC	0.07	0.04	0.06	0.04	0.05
Return on tangible assets	0.07	0.04	0.06	0.03	0.06
Graham Net	17.69	16.55	14.09	12.42	13.18
Working capital	3.59B	3.38B	3.23B	3.02B	3.03B
Tangible asset value	4.89B	4.77B	4.87B	4.71B	5.62B
Net current asset value	3.45B	3.25B	2.82B	2.54B	2.68B
Invested capital	0.01	0.02	0.02	0.02	0.07
Average receivables	236.86M	368.81M	363.69M	426.66M	434.42M
Average payables	38.98M	32.41M	37.15M	50.4M	54.82M
Average inventory	218.81M	247.56M	304.95M	420M	505.71M
Days sales outstanding	89.78	95.13	79.71	81.75	55
Days payables outstanding	36.89	30.63	34.44	30.32	22.16
Days of inventory on hand	240.65	278.8	264.06	269.78	211.63
Receivables turnover	4.07	3.84	4.58	4.46	6.64
Payables turnover	9.9	11.92	10.6	12.04	16.47
Inventory turnover	1.52	1.31	1.38	1.35	1.72
ROE	0.07	0.04	0.06	0.03	0.07
Capex per share	-2.25	-1.11	-1.54	-1.83	-1.57

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	3.04	3.56	4.09	3.95	3.96
Net income per share	0.11	0.47	0.73	0.71	0.53
Operating cash flow per share	0.29	0.63	1.17	0.63	1.47
Free cash flow per share	-0.55	0.46	0.72	0.09	1.06
Cash per share	14.88	15.23	16.59	15.59	16.38
Book value per share	32.2	32.2	33.41	33.32	33.53
Tangible book value per share	27.49	28.49	29.68	28.77	33.34
Share holders equity per share	32.2	32.2	33.41	33.32	33.53
Interest debt per share	0.72	0.96	1.36	1.61	2.24
Market cap	16.71B	17.37B	14.39B	19.38B	18.25B
Enterprise value	14.28B	14.97B	11.79B	17B	15.92B
P/E ratio	223.09	53.51	29	39.85	51.08
Price to sales ratio	32.07	28.53	20.61	28.66	27.37
POCF ratio	331.94	159.93	71.7	180.11	73.85
PFCF ratio	-176.79	219.64	116.32	1.22K	102.44
P/B Ratio	3.03	3.15	2.52	3.4	3.23
PTB ratio	3.03	3.15	2.52	3.4	3.23
EV to sales	27.42	24.58	16.88	25.14	23.87
Enterprise value over EBITDA	773.56	110.51	72.52	122.37	115.69
EV to operating cash flow	283.79	137.79	58.75	158	64.41
EV to free cash flow	-151.14	189.25	95.31	1.07K	89.35
Earnings yield	0	0	0.01	0.01	0
Free cash flow yield	-0.01	0	0.01	0	0.01
Debt to equity	0.02	0.03	0.04	0.05	0.07
Debt to assets	0.02	0.02	0.03	0.04	0.05
Net debt to EBITDA	-131.26	-17.75	-15.99	-17.12	-16.96
Current ratio	6.91	6.99	5.9	6.41	5.24
Interest coverage	3.96	80.57	42.67	156.21	32.71
Income quality	2.69	1.34	1.62	0.89	2.77
Dividend Yield	0	0	0	0	0
Payout ratio	0.55	0	0	0	0.77
Sales general and administrative to revenue	0.16	0.16	0.14	0.17	0
Research and developement to revenue	0.12	0.08	0.06	0.08	0.09
Intangibles to total assets	0.17	0.15	0.14	0.16	0.06
Capex to operating cash flow	-2.88	-0.27	-0.38	-0.85	-0.28
Capex to revenue	-0.28	-0.05	-0.11	-0.14	-0.1
Capex to depreciation	-2.7	-0.58	-1.52	-1.9	-1.43
Stock based compensation to revenue	0.01	0.01	0.01	0	0
Graham number	8.9	18.53	23.36	23.07	20
ROIC	0	0.01	0.02	0.02	0.01
Return on tangible assets	0	0.01	0.02	0.02	0.01
Graham Net	12.58	12.32	13.23	13.37	13.34
Working capital	3.02B	3.14B	3.22B	3.14B	3.03B
Tangible asset value	4.71B	4.88B	5.07B	4.93B	5.62B
Net current asset value	2.54B	2.57B	2.71B	2.7B	2.68B
Invested capital	0.02	0.03	0.04	0.05	0.07
Average receivables	449.65M	452.19M	429.98M	445.34M	430.86M
Average payables	64.11M	70.1M	86.3M	87.71M	71.8M
Average inventory	469.67M	505.99M	532.31M	551.51M	545.66M
Days sales outstanding	81.4	64.03	54.99	61.77	53.69
Days payables outstanding	26.87	38.44	33.68	43.61	19.3
Days of inventory on hand	239.08	236.34	208.38	278.54	184.31
Receivables turnover	1.11	1.41	1.64	1.46	1.68
Payables turnover	3.35	2.34	2.67	2.06	4.66
Inventory turnover	0.38	0.38	0.43	0.32	0.49
ROE	0	0.01	0.02	0.02	0.02
Capex per share	-0.85	-0.17	-0.45	-0.54	-0.41

688366.SS Dividend History

688366.SS Frequently Asked Questions

What is Shanghai Haohai Biological Technology Co., Ltd. stock symbol ?

Shanghai Haohai Biological Technology Co., Ltd. is a CN stock and trading under the symbol 688366.SS

What is Shanghai Haohai Biological Technology Co., Ltd. stock quote today ?

Shanghai Haohai Biological Technology Co., Ltd. stock price is $91.28 today.

Is Shanghai Haohai Biological Technology Co., Ltd. stock public?

Yes, Shanghai Haohai Biological Technology Co., Ltd. is a publicly traded company.

Something similar

Top by Market Cap

Company Profile

Volume Average 511.74K
Market Capitalization 14.36B
Employee 2.16K
CEO Dr. Yongtai Hou
Headquarters Shanghai,CN
IPO Date 2019-10-30
Website https://www.3healthcare.com

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. It offers ophthalmology products comprising intraocular lens, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, scalpels, etc.; orthopedics products, such as sodium hyaluronate injection and medical chitosan; wound repair products, including recombinant human epidermal growth factor for the treatment of burn wound, residual wound, donor site posttraumatic wound, and fresh or old wound of chronic ulcer; anti-adhesion materials comprising medical sodium hyaluronate gel and medical chitosan; and hemostatic materials, such as collagen sponge and porcine fibrin sealants. The company also provides medical aesthetics products comprising Matrifill, a first-generation HA dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; and radio frequency devices and laser equipment. In addition, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services; and investment and trading business. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.